Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Abvance Therapeutics Secures $3.9M Program Related Investment from The Leona M. and Harry B. Helmsley Charitable Trust for ABV100 Development

Sep 10, 2024•almost 2 years ago

Contract Type

partnership

RenoBiotechnologyBiopharma

Description

Abvance Therapeutics has secured a $3.9 million Program Related Investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust. The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate, aiming to reduce rates of hypoglycemia while allowing patients to pursue tighter glycemic control.

Company Information

Company

Abvance Therapeutics

Location

Reno, Nevada, United States

About

Abvance Therapeutics, Inc. is a privately held biotechnology company advancing novel glucagon-based therapies designed to integrate into the lived experience of diabetes care. Founded on research from Vanderbilt University and led by a team with expertise in diabetes therapeutics, drug development, and health technology.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Abvance Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.